|
DHX33 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.73709943598988E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.63530000651946E-09 |
| Normal-vs-Stage2 |
3.577900E-04 |
| Normal-vs-Stage3 |
4.32699986951945E-10 |
| Normal-vs-Stage4 |
3.671399995131E-08 |
| Stage1-vs-Stage2 |
2.382800E-01 |
| Stage1-vs-Stage3 |
1.984550E-01 |
| Stage1-vs-Stage4 |
3.409200E-01 |
| Stage2-vs-Stage3 |
4.707800E-02 |
| Stage2-vs-Stage4 |
7.388200E-02 |
| Stage3-vs-Stage4 |
9.765800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.65200125485421E-11 |
| Normal-vs-AfricanAmerican |
2.343500E-03 |
| Normal-vs-Asian |
1.25589999999676E-06 |
| Caucasian-vs-AfricanAmerican |
3.016200E-01 |
| Caucasian-vs-Asian |
7.562200E-01 |
| AfricanAmerican-vs-Asian |
2.754200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.18659534922949E-11 |
| Normal-vs-Female |
1.10590003821187E-09 |
| Male-vs-Female |
1.179770E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.40189999608964E-08 |
| Normal-vs-Age(41-60Yrs) |
3.32250005286028E-10 |
| Normal-vs-Age(61-80Yrs) |
8.99119999564491E-08 |
| Normal-vs-Age(81-100Yrs) |
1.616210E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.517600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.777400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.429800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.124800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.929000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.779800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.020300E-02 |
| Classical-VS-Follicular |
4.632000E-01 |
| Classical-VS-Other |
1.628760E-01 |
| Classical-VS-Normal |
2.94970003977824E-09 |
| Tall-VS-Follicular |
2.150600E-01 |
| Tall-VS-Other |
5.866400E-01 |
| Tall-VS-Normal |
2.88309999985081E-07 |
| Follicular-VS-Other |
3.068000E-01 |
| Follicular-VS-Normal |
3.49779999964106E-07 |
| Other-VS-Normal |
1.176620E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.24030002829545E-09 |
| Normal-vs-N1 |
2.65629999995909E-07 |
| N0-vs-N1 |
4.579400E-01 |
|
|
